Lexaria Bioscience Corp.
LEXX · NASDAQ
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.38 | 0.54 | -0.19 |
| FCF Yield | -19.20% | -5.82% | -7.86% | -3.82% |
| EV / EBITDA | -3.78 | -7.06 | -10.06 | -20.41 |
| Quality | ||||
| ROIC | -70.99% | -40.16% | -28.16% | -28.16% |
| Gross Margin | 100.00% | 100.00% | 98.52% | 100.00% |
| Cash Conversion Ratio | 0.95 | 0.55 | 1.01 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.65% | 16.53% | 13.15% | 22.05% |
| Free Cash Flow Growth | -139.27% | 45.05% | -39.00% | -52.26% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 2.31 | 2.99 | 2.89 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 185.24 | 171.29 | -8,543.29 | 165.51 |